Bone Health and Linear Growth in Children With Familial Hypoparathyroidism Treated With Human Parathyroid Hormone 1-34
Authors' conclusion
Our study highlights distinct growth and BMD patterns in APS-1 and CaR and underscores the need for careful monitoring and tailored treatment strategies to optimize growth and bone health.
Study context
- Population
- Children with familial hypoparathyroidism (APS-1 or activating CaR variant) treated with parathyroid hormone (PTH) 1–34; mean baseline age 13.7 ± 5.5 years
- Participants
- 18 vs 9
- Comparison
- APS-1 vs CaR hypoparathyroidism during PTH 1-34 therapy
- APS-1n = 18
- CaRn = 9
- Primary endpoint
- Associations of age and PTH therapy duration with height Z-score (HAZ), LS-BMD-Z and LS-TBS-Z
Methodological detailslongitudinal mixed-effects modeling
- Longitudinal mixed-effects modeling
Primary result
As reported in the abstract
HAZ, LS-BMD-Z and LS-TBS-Z by age and PTH duration · during PTH therapy
- Mean LS-BMD-Z normal (BMD-Z: 0 ± 1) in both groups
- Mean LS-TBS-Z near or above 0 and differed by group
- APS-1 vs CaR: age by group interaction P < .0001
- APS-1 vs CaR: time by group interaction P = .02
Further findings
APS-1 disease severity and LS-BMD-Z / LS-TBS-Z
- APS-1 with greater severity (≥7 manifestations) had lower LS-BMD-Z and LS-TBS-Z than less severe APS-1 or CaR
Original publication
Bone Health and Linear Growth in Children With Familial Hypoparathyroidism Treated With Human Parathyroid Hormone 1-34. J Clin Endocrinol Metab. Published 30 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →